Fibromuscular dysplasia screening: Difference between revisions

	Fibromuscular dysplasia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fibromuscular dysplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiorgram
X-ray
CT
MRI
Arteriography
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Management Guidelines
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
ASA/ACCF/AHA Guideline Recommendations
Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries
Case Studies
Case #1
Fibromuscular dysplasia screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Fibromuscular dysplasia screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Fibromuscular dysplasia screening
CDC on Fibromuscular dysplasia screening
Fibromuscular dysplasia screening in the news
Blogs on Fibromuscular dysplasia screening
Directions to Hospitals Treating Fibromuscular dysplasia
Risk calculators and risk factors for Fibromuscular dysplasia screening

Revision as of 03:14, 15 June 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

According to the American Heart Association (AHA)/American College of Cardiology guidelines, and European consensus on the diagnosis and management of fibromuscular dysplasia among patients with HTN, screening for FMD-related RAS is recommended in the following indications:
1. Age <30 years, especially in women
2. Grade 3 (_180/110 mmHg), accelerated or malignant HTN,
3. Resistant HTN (blood pressure target not achieved despite triple therapy at optimal doses including a diuretic)
4. Small kidney without history of uropathy
5. Abdominal bruit without apparent atherosclerosis
6. FMD in at least another vascular territory

@@ Line 6: / Line 6: @@
 ==Screening==
-There is insufficient evidence to recommend routine screening for [disease/malignancy].
+*According to  the American Heart Association (AHA)/American College of Cardiology guidelines, and European consensus on the diagnosis and management of fibromuscular dysplasia  among patients with HTN, screening for FMD-related RAS is recommended in the following indications:
+*1. Age <30 years, especially in women
-OR
+*2. Grade 3 (_180/110 mmHg), accelerated or malignant HTN,
+*3. Resistant HTN (blood pressure target not achieved despite triple therapy at optimal doses including a diuretic)
-According to the [guideline name], screening for [disease name] is not recommended.
+*4. Small kidney without history of uropathy
+*5. Abdominal bruit without apparent atherosclerosis
-OR
+*6. FMD in at least another vascular territory
-According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
-*[Condition 1]
-*[Condition 2]
-*[Condition 3]
 ==References==